In this phase II trial, we will evaluate the weekly schedule of topotecan in the first-line treatment of elderly and/or poor performance status patients with extensive stage small cell lung cancer. Patients eligible for this trial will be those considered poor candidates for standard combination chemotherapy or other investigational regimens
Upon determination of eligibility, all patients will be receive: * Topotecan
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
Overall response rate
Median survival
1 year and 2 year survival
Overall toxicity
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.